Abu Dhabi has become the first in the world to deliver Itvisma, a one-time gene therapy specifically designed to target the underlying genetic cause of spinal muscular atrophy (SMA) in patients aged two years and above.
Sheikh Khalifa Medical City (SKMC) has successfully administered this groundbreaking gene therapy, developed by Novartis, under the supervision of the Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the emirate.
The therapy had been previously approved by the UAE on November 25, positioning it among the first countries globally, after the USA, to endorse the pioneering treatment.
Designed for simplicity long-term impact, Itvisma (onasemnogene abeparvovec) replaces the missing SMN1 gene to improve motor function, reducing the need for continuous treatments required by other therapies.
Dr. Noura Khamis Al Ghaithi, Under-Secretary of DoH, stated that “this milestone reflects Abu Dhabi’s commitment to delivering world class care and strengthening its position as a global leader in healthcare driven by genomics and precision medicine."
UAE backs IMO move urging Iran to halt actions endangering Arabian Gulf waters
UAE calls for immediate, unconditional reopening of Strait of Hormuz
UAE reaffirms support for Bahrain’s sovereign measures to safeguard national security
H.H. Sheikh Mohammed hails first batch to secure government scholarships
WATCH: Driver caught in Dubai for running red light without number plate
Abu Dhabi tests autonomous patrol boats to boost maritime safety
UAE charges 13 people, 6 firms in Port Sudan arms trafficking case
UAE bans citizens from travel to Iran, Lebanon and Iraq
